PASI 90 and absolute PASI: why we should change goals treatment in psoriasis?
DOI:
https://doi.org/10.29176/2590843X.1490Keywords:
Psoriasis, Health related quality of life (HRQOL), Treatment outcomes, Severity scale, Treatment goalAbstract
In 2011 a European consensus defined the target treatment of psoriasis, with PASI 75 as the main objective and had been adopted in guidelines around the world. In those 9 years the progress of the medications to treat psoriasis have been able to obtain an almost clear skin. Current literature promotes PASI 90, PASI absolute and patient reported outcomes as the goal of recent treatments. PASI 90 and PASI absolute <3 have a strong relationship with DLQI 0-1 and permit to measure the satisfaction of patients and doctors with the psoriasis treatments. This is the moment to move forward to current and realistic goals.
Author Biographies
Natalia Hernández Mantilla
Dermatóloga, MSc en Economía de la Salud y del Medicamento.
Ángela Londoño García
Dermatóloga, MSc en Epidemiología. Coordinadora, Especialización en Dermatología, Universidad CES, Medellín.
References
1. Strober BE, van der Walt JM, Armstrong AW, Bour¬cier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9(1):5-18. doi: 10.1007/s13555-018-0279-5.
2. Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Mulleger R, Sator P, Ratzinger G, Selhofer S, Richter L, Salmhofer W, Lange-Asschenfeldt B, et al. Quality of life and treatment goals in psoriasis from the patient perspective: re¬sults of an Austrian cross-sectional survey. J Dtsch Dermatol Ges. 2018;16(8):981-91. doi: 10.1111/ddg.13613_g.
3. Puig L. PASI 90 response: the new standard in therapeutic efficacy in psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645-8. doi: 10.1111/jdv.12817.
4. Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Complete skin clearance and Psoriasis area and severity index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2020;182(4):965-73. doi: 10.1111/bjd.18361.
5. Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic derma¬titis. J Am Acad Dermatol. 2019;81(4):943-49. doi: 10.1016/j.jaad.2019.06.018.
6. Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vila¬rrasa E, del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral S, et al. Redefining the therapeutic objec¬tive in psoriatic patients candidates for biological therapy. J Dermatol Treat. 2018;29(4):334-46. doi: 10.1080/09546634.2017.1395794.
7. Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related qua¬lity of life. J Dermatolog Treat. 2020;13:1-6. doi: 10.1080/09546634.2020.1746734.
8. Movrietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, et al. Definition of treatment goals for mode¬rate and severe psoriasis: a European con¬sensus. Arch Dermatol Res. 2011;303(1):1-10. doi: 10.1007/s00403-010-1080-1.
9. Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology. French gui¬delines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-83. doi: 10.1111/jdv.15340.
10. Maul JT, Navarini AA, Sommer R, Anzen¬gruber R, Sorbe C, Mrovietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kie¬drowski R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis-a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700-8. doi: 10.1111/jdv.15324.
11. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, et al. Psoriasis treat to target: definition outcome in psoriasis using data from a real world population based cohort study (the British Association of Dermato¬logist Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158-66. doi: 10.1111/bjd.18333.
12. Kouwenhoven TA, van der Ploeg JAM, Van der Kerkhof. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13-17. doi: 10.1080/09546634.2018.1544408.
2. Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Mulleger R, Sator P, Ratzinger G, Selhofer S, Richter L, Salmhofer W, Lange-Asschenfeldt B, et al. Quality of life and treatment goals in psoriasis from the patient perspective: re¬sults of an Austrian cross-sectional survey. J Dtsch Dermatol Ges. 2018;16(8):981-91. doi: 10.1111/ddg.13613_g.
3. Puig L. PASI 90 response: the new standard in therapeutic efficacy in psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645-8. doi: 10.1111/jdv.12817.
4. Norlin JM, Nilsson K, Persson U, Schmitt-Egenolf M. Complete skin clearance and Psoriasis area and severity index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2020;182(4):965-73. doi: 10.1111/bjd.18361.
5. Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic derma¬titis. J Am Acad Dermatol. 2019;81(4):943-49. doi: 10.1016/j.jaad.2019.06.018.
6. Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vila¬rrasa E, del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral S, et al. Redefining the therapeutic objec¬tive in psoriatic patients candidates for biological therapy. J Dermatol Treat. 2018;29(4):334-46. doi: 10.1080/09546634.2017.1395794.
7. Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related qua¬lity of life. J Dermatolog Treat. 2020;13:1-6. doi: 10.1080/09546634.2020.1746734.
8. Movrietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, et al. Definition of treatment goals for mode¬rate and severe psoriasis: a European con¬sensus. Arch Dermatol Res. 2011;303(1):1-10. doi: 10.1007/s00403-010-1080-1.
9. Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology. French gui¬delines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-83. doi: 10.1111/jdv.15340.
10. Maul JT, Navarini AA, Sommer R, Anzen¬gruber R, Sorbe C, Mrovietz U, Drach M, Blome C, Boehncke WH, Thaci D, Reich K, von Kie¬drowski R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis-a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700-8. doi: 10.1111/jdv.15324.
11. Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, et al. Psoriasis treat to target: definition outcome in psoriasis using data from a real world population based cohort study (the British Association of Dermato¬logist Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158-66. doi: 10.1111/bjd.18333.
12. Kouwenhoven TA, van der Ploeg JAM, Van der Kerkhof. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13-17. doi: 10.1080/09546634.2018.1544408.
How to Cite
1.
Hernández Mantilla N, Londoño García Ángela. PASI 90 and absolute PASI: why we should change goals treatment in psoriasis?. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2020 Aug. 21 [cited 2024 Jul. 22];28(1):58-62. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1490
Downloads
Download data is not yet available.
Downloads
Published
2020-08-21
How to Cite
1.
Hernández Mantilla N, Londoño García Ángela. PASI 90 and absolute PASI: why we should change goals treatment in psoriasis?. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2020 Aug. 21 [cited 2024 Jul. 22];28(1):58-62. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1490
Issue
Section
Reflection article
License
Copyright (c) 2020 Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
